研究目的
To assess the efficacy of a low-power fractional CO2 laser alone versus its combination with tranexamic acid used either topically or intradermally for melasma treatment.
研究成果
A low-power fractional CO2 laser is an effective, safe treatment for melasma. However, the addition of tranexamic acid (either topically or intradermally) to a fractional CO2 laser should be further studied.
研究不足
The study had a small sample size and did not include a long-term follow-up to assess the longevity of the treatment effects. The method of administration of TXA was only prior and immediately after laser sessions, which may not be as effective as more frequent applications.
1:Experimental Design and Method Selection:
A randomized comparative split-face study was conducted.
2:Sample Selection and Data Sources:
Thirty female patients with bilateral, symmetrical melasma were included.
3:List of Experimental Equipment and Materials:
Fractional CO2 laser (DEKA, SMARTXIDE DOT, Italy), tranexamic acid solution (Kapron 500 mg/5 ml ampoules, Amoun Pharmaceutical Company), topical anesthetic cream (lidocaine 25% and prilocaine 25%).
4:Experimental Procedures and Operational Workflow:
Five consecutive sessions, 4–6 weeks apart, were performed by fractional CO2 laser. One side was treated with fractional CO2 laser alone, and the other side was treated with fractional CO2 laser combined with TXA (topically or intradermally).
5:Data Analysis Methods:
Assessments were done using the melasma area severity index MASI score, melanin index (MI), and erythema index (EI).
独家科研数据包,助您复现前沿成果,加速创新突破
获取完整内容